AbbVie has agreed to pay $700 million upfront to acquire rights to ISB 2001, a trispecific antibody developed by Ichnos Glenmark Therapeutics targeting multiple myeloma. The antibody engages CD3 on T cells alongside BCMA and CD38 proteins on cancer cells, offering a triple mechanism for tumor clearance. The deal includes milestone payments up to $1.23 billion and royalties upon commercialization, with AbbVie obtaining rights in North America, Europe, Japan, and China; Ichnos will retain responsibility in emerging markets. Early-phase clinical data shows a 79% overall response rate in relapsed or refractory patients, with good tolerability. The FDA has granted orphan drug and fast track designations to ISB 2001, facilitating its regulatory development. AbbVie also plans to explore autoimmune indications for this therapeutic modality.